Abstract
Background
Inflammatory mediators play a key role in the development and progression of heart failure. Interleukin-1β (IL-1β) is a prototypical inflammatory cytokine that suppresses myocyte contractility following acute administration.
Methods
Healthy mice were randomly assigned to daily intraperitoneal injections of recombinant murine IL-1β (3 μg/kg in 0.2 ml) or matching volumes of NaCl 0.9 % solution (vehicle) for 15 days. Echocardiography was performed at baseline and 4 h (acute), followed by repeat measurements immediately prior to IL-1β or saline injections on days 5, 10, and 15 (chronic). Final echocardiography was performed on day 20 (5 days after last treatment). A subgroup of animals underwent isoproterenol challenge to evaluate contractile reserve at baseline, 4 h (acute), 15 days (chronic) and 20 days (recovery).
Results
IL-1β reduced left ventricular fractional shortening (LVFS) at 4 h versus vehicle (−24 vs. 0 %, respectively, P < 0.05). This reduction was maintained throughout chronic dosing at day 15. IL-1β-treated mice also showed impaired contractile reserve with a right shift of the dose-response curve to isoproterenol (P < 0.05) at 4 h and 15 days. By day 20, 5 days after stopping IL-1β, LVFS and contractile reserve had returned to baseline.
Conclusions
IL-1β induces a reversible contractile dysfunction associated with impaired response to β-receptor stimulation.
References
Weintraub NL, Collins SP, Pang PS, Levy PD, Anderson AS, Arslanian-Engoren C, Gibler WB, McCord JK, Parshall MB, Francis GS, Gheorghiade M. Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. Circulation. 2010;122:1975–96.
Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics – 2012 update: a report from the American Heart Association. Circulation. 2012;125:e2–220.
Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001;103:2055–9.
Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117:3720–32.
Van Tassell BW, Arena RA, Toldo S, Mezzaroma E, Azam T, Seropian IM, Shah K, Canada J, Voelkel NF, Dinarello CA, Abbate A. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One. 2012;7:e33438.
Gardin JM, Adams DB, Douglas PS, Feigenbaum H, Forst DH, Fraser AG, Grayburn PA, Katz AS, Keller AM, Kerber RE, Khandheria BK, Klein AL, Lang RM, Pierard LA, Quinones MA, Schnittger I. Recommendations for a standardized report for adult transthoracic echocardiography: a report from the American Society of Echocardiography’s Nomenclature and Standards Committee and Task Force for a Standardized Echocardiography Report. J Am Soc Echocardiogr. 2002;15:275–90.
Bristow MR. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol 1993;22(4 Suppl A):61A-71A.
Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, Damske BA, Parrillo JE. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med. 1985;100:483–90.
Smith LM, McDonough KH. Inotropic sensitivity to β-adrenergic stimulation in early sepsis. Am J Physiol Heart Circ Physiol. 1988;255:H699–703.
Abbate A, Van Tassell BW, Biondi-Zoccai GGL. Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events. Biodrugs. 2012;26:217–33.
Liu SJ, Zhou W, Kennedy RH. Suppression of beta-adrenergic responsiveness of L-type Ca2+ current by IL-1beta in rat ventricular myocytes. Am J Physiol. 1999;276:H141–8.
Gulick T, Chung MK, Pieper SJ, Lange LG, Schreiner GF. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte β-adrenergic responsiveness. Proc Natl Acad Sci USA. 1989;86:6753–7.
Kumar AR, Brar R, Wang P, Dee L, Skorupa G, Khadour F, Schulz R, Parrillo JE. Role of nitric oxide and cAMP in human septic serum-induced depression of cardiac myocyte contractility. Am J Physiol. 1999;276:R265–76.
Kan H, Finkel MS. Inflammatory mediators and reversible myocardial dysfunction. J Cell Physiol. 2003;195:1–11.
Garan AR, Uriel N, Sayer G, Sims D, Zahner D, Farr M, Mancini D, Jorde UP. Alteration in systemic vascular resistance and cardiac output during acute cellular rejection and recovery in heart transplant recipients. J Heart Lung Transplant. 2010;29:382–4.
Cooper LT. Myocarditis. N Engl J Med. 2009;360:1526–38.
Chockalingam A, Mehra A, Dorairajan S, Dellsperger KC. Acute left ventricular dysfunction in the critically ill. Chest. 2010;138:198–207.
Neil CJ, Nguyen TH, Sverdlov AL, Chirkov YY, Chong CR, Stansborough J, Beltrame JF, Kucia AM, Zeitz CJ, Frenneaux MP, Horowitz JD. Can we make sense of takotsubo cardiomyopathy? An update on pathogenesis, diagnosis and natural history. Expert Rev Cardiovasc Ther. 2012;10(2):215–21.
Acknowledgments
Dr. Van Tassell is supported by an Institutional National Institute of Health K12 development grant. Dr. Mezzaroma is supported by an American Heart Association Post-doctoral Fellow Award. Dr. Abbate is supported by an American Heart Association Scientist Development Grant.
Conflict of interest
In the past 12 months, Dr. Abbate has received consultant fees from Biovitrum and XOMA, and has received research support from Novartis.
Author information
Authors and Affiliations
Corresponding author
Additional information
Responsible Editor: John Di Battista.
Rights and permissions
About this article
Cite this article
Van Tassell, B.W., Seropian, I.M., Toldo, S. et al. Interleukin-1β induces a reversible cardiomyopathy in the mouse. Inflamm. Res. 62, 637–640 (2013). https://doi.org/10.1007/s00011-013-0625-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00011-013-0625-0